A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.
[read full story]
By Will Dunham WASHINGTON (Reuters) - The drug is finasteride, formerly sold by Merck and Co as Proscar to treat enlargement of the prostate and now available generically. When the initial results of the study were announced, the researchers cautioned that men in the study who developed prostate...
By Steven Reinberg HealthDay Reporter 19 minutes ago TUESDAY, May 20 (HealthDay News) -- "What we are showing today is that there is a significant difference between men who were treated with radiation and those who weren't," study co-author Dr. Gregory P. Swanson, of Cancer Care Northwest...
TUESDAY, May 20 (HealthDay News) -- Prostate-specific antigen (PSA) is a protein produced by the cells in the prostate; because PSA can be used to detect disease, it is sometimes called a biological marker or tumor marker, according to the National Cancer Institute. The examinations included PSA...
A re-analysis of data from the landmark Prostate Cancer Prevention Trial (PCPT) finds that finasteride reduces the risk for prostate cancer without boosting the odds of aggressive tumors. So when we accounted for this shrinkage in prostate volume, the disparity in tumor aggressiveness between the...
Description A re-analysis of data from the landmark Prostate Cancer Prevention Trial (PCPT) finds that finasteride reduces the risk for prostate cancer without boosting the odds of aggressive tumors. Newswise — A re-analysis of data from the landmark Prostate Cancer Prevention Trial (PCPT) finds...
A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.
ORLANDO, May 20 -- For men with low-risk, localized prostate cancer, active surveillance remains a viable option, but not without a "small but very real" risk, new data suggest. During 30 months of follow-up, the need for intervention could be predicted by characteristics of the first and second...
A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.A pathologic analysis of that...
eiNav/Artemis Helps Pinpoint Prostate Cancer, Provides a Map for Follow-up CareGRASS VALLEY, Calif.--(BUSINESS WIRE)--A new imaging device, eiNav/Artemis, now officially cleared by the U.S. Food and Drug Administration (FDA), offers urologists breakthrough technology that will significantly help...
DURHAM, N.C. -- Doctors may be missing cancers in obese men because the telltale blood marker used to detect the disease can be falsely interpreted as low in this population, according to a new study led by Duke Prostate Center researchers."Obese men have more blood circulating throughout their...